News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

Parkinson Disease

Latest News

December 2nd 2022

Episode 78: A Virtual Reality Platform for Parkinson Disease

By Matt Hoffman

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jay Alberts, PhD. [LISTEN TIME: 27 minutes]

Latest Videos

Adjusting Motor Fluctuation Management in an Era of Neuromodulation: Laxman Bahroo, DO

Adjusting Motor Fluctuation Management in an Era of Neuromodulation: Laxman Bahroo, DO

CUE1 Device, a Vibrational Therapy to Potentially Treat Parkinson Disease Symptoms: Alistair Mackett, MD

CUE1 Device, a Vibrational Therapy to Potentially Treat Parkinson Disease Symptoms: Alistair Mackett, MD

The Changing Landscape of Parkinson Disease and New Therapies on the Horizon: Mazen Elkurd, DO

The Changing Landscape of Parkinson Disease and New Therapies on the Horizon: Mazen Elkurd, DO

The Impact of Social Participation on Cognitive Function in Patients With Parkinson Disease: Ling Wan-Albert, OTD, OTR/L

The Impact of Social Participation on Cognitive Function in Patients With Parkinson Disease: Ling Wan-Albert, OTD, OTR/L

Emerging Therapies in Movement Disorders and Chronic Care Management for Parkinson Disease: Safia Abdillahi, ACNP-BC, DNP

Emerging Therapies in Movement Disorders and Chronic Care Management for Parkinson Disease: Safia Abdillahi, ACNP-BC, DNP

The Rising Prevalence and Behavioral Implications of Dementia in Parkinson Disease: Nahid Mohammadzadeh, MD

The Rising Prevalence and Behavioral Implications of Dementia in Parkinson Disease: Nahid Mohammadzadeh, MD

A Multifaceted Approach to Understanding ON and OFF Periods in Parkinson Disease: Salima Brillman, MD

A Multifaceted Approach to Understanding ON and OFF Periods in Parkinson Disease: Salima Brillman, MD

Trichloroethylene Exposure and Usage, Environmental Associations in Parkinson Disease: Samuel M. Goldman, MD, MPH

Trichloroethylene Exposure and Usage, Environmental Associations in Parkinson Disease: Samuel M. Goldman, MD, MPH

Environmental Exposures and the Impact of Trichloroethylene on Parkinson Disease: Samuel M. Goldman, MD, MPH

Environmental Exposures and the Impact of Trichloroethylene on Parkinson Disease: Samuel M. Goldman, MD, MPH

Future of Treating Parkinson Disease Psychosis, Overcoming Challenges in Clinical Trials: Aaron Ritter, MD

Future of Treating Parkinson Disease Psychosis, Overcoming Challenges in Clinical Trials: Aaron Ritter, MD

CME Content

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

James F. Howard Jr, MD, FAAN

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Karissa Gable, MD

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Basil T. Darras, MD

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Anne M. Connolly, MD, FAAN; Amy Moore, PhD

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Jessica Oswald, MD, MPH; Jeremy A. Adler, DMSc, PA-C; Amanda Nasser, MS, NP

Expert Illustrations & Commentaries�™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Katherine Ruzhansky, MD, MS

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA, FASCO; Girish Dhall, MD

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Millie Das, MD; Wade Iams, MD, MSCI; Ruham Nasany, MD

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Abigail Schwaede, MD; Alexis Lizarraga, MD, MS

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

More News

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Former NFL Running Back Chris Johnson Diagnosed With ALS at 40

FDA Accepts Sarepta's sNDAs for Casimersen and Golodirsen for Duchenne Muscular Dystrophy

Long-Term Efficacy of Anti-CD20 Therapies in MS: What the Evidence Shows

FDA Aligns With Cognition Therapeutics on Phase 3 Trial Design for Zervimesine in DLB-Associated Psychosis

Managing Infection Risk and Safety Monitoring with Anti-CD20 MS Disease Modifying Therapy